Trial Profile
Prospective, Observational, Multicentre Study Evaluating HCV Patients Characteristics of Eligibility and Disease Management in Real Clinical Practice
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2b (Primary) ; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Merck & Co; Merck Sharp & Dohme Corp.; Schering-Plough
- 08 Nov 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 22 Sep 2011 Planned end date changed from 1 Aug 2011 to 1 Oct 2011 as reported by ClinicalTrials.gov.
- 09 Dec 2010 Planned End Date changed from 1 Jun 2011 to 1 Aug 2011 as reported by ClinicalTrials.gov.